{"id":"amivantamab-intravenous","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Infusion-related reactions"},{"rate":"30-40","effect":"Rash"},{"rate":"20-30","effect":"Paronychia"},{"rate":"20-25","effect":"Diarrhea"},{"rate":"15-20","effect":"Nausea"},{"rate":"15-20","effect":"Fatigue"},{"rate":"10-15","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL4297774","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amivantamab targets two key oncogenic pathways by engaging both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). By binding both receptors, it prevents ligand-induced activation and promotes antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), leading to direct tumor cell killing and immune activation.","oneSentence":"Amivantamab is a bispecific monoclonal antibody that simultaneously binds to EGFR and MET receptors, blocking their signaling and triggering immune-mediated tumor cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:26.636Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations"},{"name":"EGFR-mutant NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors"}]},"trialDetails":[{"nctId":"NCT06667076","phase":"PHASE2","title":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":480},{"nctId":"NCT04538664","phase":"PHASE3","title":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-10-13","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":308},{"nctId":"NCT05379595","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-29","conditions":"Advanced or Metastatic Colorectal Cancer","enrollment":225},{"nctId":"NCT04077463","phase":"PHASE1","title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":701},{"nctId":"NCT05388669","phase":"PHASE3","title":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-05","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":418},{"nctId":"NCT05908734","phase":"PHASE1, PHASE2","title":"A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-05-18","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":71},{"nctId":"NCT06385080","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-22","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":287},{"nctId":"NCT05488314","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-12-13","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":57},{"nctId":"NCT06532032","phase":"PHASE1, PHASE2","title":"A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-07-23","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":12},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT02609776","phase":"PHASE1","title":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-24","conditions":"Non-Small-Cell Lung Cancer","enrollment":751},{"nctId":"NCT04965090","phase":"PHASE2","title":"A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-09-30","conditions":"Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer","enrollment":43},{"nctId":"NCT06784791","phase":"PHASE2","title":"Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)","status":"RECRUITING","sponsor":"University Hospital, Essen","startDate":"2024-11-06","conditions":"Lung Cancer (NSCLC)","enrollment":20},{"nctId":"NCT04945733","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-08-30","conditions":"Stomach Neoplasms, Esophageal Neoplasms","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JNJ-61186372","Chemotherapy"],"phase":"phase_3","status":"active","brandName":"Amivantamab Intravenous","genericName":"Amivantamab Intravenous","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amivantamab is a bispecific monoclonal antibody that simultaneously binds to EGFR and MET receptors, blocking their signaling and triggering immune-mediated tumor cell death. Used for Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, EGFR-mutant NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}